European Journal of Molecular & Clinical Medicine

Abstract

The genome editing technology has become a powerful method for creating genetically modified cells and organisms, necessary for the genes function and mechanisms of human disease determination. The clustered system with regularly interspaced short palindromic repeats (CRiSPR-), associated with9 (Cas9), quickly became one of the world’s major approaches to genome editing in basic biomedical research in recent years as a result of its simplicity and adaptability.
Genome editing CRiSPR/Cas9 werebeing used for correction mutating people's DNA from one base pair to large deletions both in vitro and in vivo. Model systems CRISPR/Cas9 are usedfor a better understanding of many aspects of cardiovascular disease, including lipid metabolic, electrophysiology and genetic heritage. CRiSPR/Cas9 technology has been proven to be effective for editing induced pluripotent stem cells. In spite of these gains, some biological, technical and ethical problems limit therapeutic capacity to edit the genome by cardiovascular diseases. The purpose of the study is to analyze the applications of CRiSPR/Cas9 genome editing in the cardiovascular system, for both disease research and treatment prospects by editing the genome in vivo in the future.